Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Key Highlights
- ➤Mirum grants 18,663 stock options and 24,687 RSUs to 18 new employees
- ➤New CMO Rob Myers receives 40,000 stock options and 25,000 RSUs
- ➤Options carry an $86.01 exercise price and vest over four years
- ➤RSUs vest over three years, subject to continued employee service
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on October 9, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 18,663 shares of common stock and 24,687 restricted stock units (“RSUs”) to 18 new employees under Mirum’s 2020 Inducement Plan. Additionally, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 40,000 shares of common stock and 25,000 RSUs under Mirum’s 2020 Inducement Plan to the company’s newly appointed Chief Medical Officer, Rob Myers, M.D. The Compensation Committee of Mirum’s Board of Directors approved the awards to Dr. Myers and the other employees as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Get started
Create a free account to read the full story.